Real-World Data Shows Promise for Advanced Melanoma Patients
Source: Mescape, March 2025
Hello. I’m Dr Maurie Markman, from City of Hope. I’d like to present what I consider to be very important and positive objective data regarding the impact that we are having on the management of cancer, in general, and advanced cancers in particular. The paper I’m referring to is entitled, “Long-term survival in patients with advanced melanoma,” published in JAMA Network Open.
I’m referring to a cohort study from the Netherlands using data from the Dutch Melanoma Treatment Registry. These are real-world data we’re referring to here. We’re not talking about clinical trials. We’re not going to talk about patients who were selected based upon excellent performance status. We’re talking about real-world patients in this registry who received first-line immune checkpoint inhibitors for advanced melanoma.
In my day, if someone had advanced melanoma and they were beyond the point where it could be potentially resected surgically, survival for the vast majority of patients was measured in months. Sometimes it could be longer, but we did not have effective therapies.